The PCSK9 gene is considered a potential target for gene-editing therapy due to naturally occurring loss-of-function mutations that lead to lifelong low circulating LDL-C levels and an 88% relative risk reduction for ASCVD without adverse long-term effects [85]. Here, PCSK9 is linked to atherosclerosis.